Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner(LMU Klinikum), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Hermann Einsele(Universitätsklinikum Würzburg), Roland Repp(Klinikum Oldenburg), Hans-Peter Böck(Klinikum Oldenburg), Martin Dreyling(LMU Klinikum), Annette Hänel(Klinikum Oldenburg), John F. Seymour(The Royal Melbourne Hospital), Frank Hartmann(Universität Hamburg), H. Wandt(Klinikum Oldenburg), Michael Unterhalt, Thomas Lehmann(Jena University Hospital), Christiane Pott(University Hospital Schleswig-Holstein), Bernd Metzner(Klinikum Oldenburg)
Cited by 465
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k